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Superior vena cava (SVC) syndrome is a group of clinical signs caused by the obstruc-
tion or compression of SVC and characterized by edema of the head, neck, and upper 
extremities, shortness of breath, and headaches. The syndrome may be caused by 
benign causes but most of the cases are caused by lung or mediastinal malignant 
tumors. Stenting of SVC has become widely accepted as the palliative treatment for this 
condition in malignant diseases, as it offers rapid relief of symptoms and improves the 
quality of life. Preserving previously placed central venous catheters (CVCs) is a major 
issue in this population. We report the case of a patient with SVC syndrome caused 
by tumoral obstruction due to central small-cell lung cancer who had right subclavian 
implanted CVC and a preferential head and neck venous drainage through the left inter-
nal jugular and brachiocephalic vein (BCV). We describe a complex procedure of SVC 
reconstruction with two different objectives: left recanalization and stent placement to 
ensure head and neck venous drainage and right BCV stenting for CVC repositioning 
and subsequent replacement. We also review published cases of SVC obstructions 
stenting with catheter repositioning. The patient experienced quick relief of symptoms 
after treatment. Chemotherapy was rapidly delivered through the preserved implanted 
CVC access. A 3-month follow-up computed tomography showed stents patency.
Keywords: superior vena cava syndrome, endovascular stenting, lung cancer, central venous catheter protection, 
vena cava obstruction
INtRoDUCtIoN
Endovascular stent-based revascularization is used as a therapeutic measure in patients with supe-
rior vena cava (SVC) obstructions (1). It does not interfere with subsequent antitumor treatments 
and provides urgent relief of symptoms (2, 3). Additionally, stenting greatly improves the quality of 
life of patients (4–7) with a good long-term patency, especially in patients with benign causes (1). 
Revascularization in patients with malignant causes of obstructions aims of course to ensure venous 
drainage but also in several cases where the patient had or need the central venous catheters (CVCs) 
to preserve the CVC function and/or route for insertion. We report the history of a patient who devel-
oped SVC syndrome due to extensive extravascular tumor-related obstruction and who previously 
FIgURe 1 | Digital subtraction phlebography from the left (a) and right (B) subclavian veins showed superior vena cava and both the right and left brachiocephalic 
vein stenosis with collateral channels.
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received implanted CVC for the purpose of chemotherapy. The 
endovascular approach consisted on treating venous obstructions 
while preserving the CVC function using bilateral asymmetric 
stenting and endovascular CVC-repositioning maneuvers.
Case pReseNtatIoN
patient
A 60-year-old male patient with central small-cell lung cancer 
having brain, adrenal gland, and bones metastasis (stage IV) 
underwent right-sided subclavian CVC implantation 3 months 
ago for a first-line chemotherapy (cisplatin and etoposide).
He was admitted to the emergency department with symptoms 
suggestive of SVC syndrome, including distended collateral neck 
veins, plethora of the face, and dyspnea.
Computed tomography (CT) chest venography evidenced 
central tumor growth with the obstruction of the SVC and the 
encirclement of both brachiocephalic veins (BCVs). Neither 
endoluminal component nor thrombus formation was identified. 
The left internal jugular vein (IJV) was larger than the right, cor-
responding to a major left venous return from the head and neck.
The diagnosis of subacute SVC syndrome related to tumor 
progression was established. To provide rapid relief of severe 
venous congestion and its associated morbidity, endovascular 
management was decided.
The CVC was still functional on radiographic evaluation. In an 
attempt to preserve the CVC for any subsequent chemotherapy, 
we opted to deploy two kissing stents in order to cover the SVC 
downstream and both BCVs. The CVC tip had to be moved into 
the ipsilateral BCV before stent placement. A written consent was 
obtained from the patient.
procedure
We performed the procedure in the radiology vascular-operating 
room using X-ray guidance under local anesthesia (10 mL of 1% 
lidocaine) with conscious sedation (intravenous administration 
of 1 mg midazolam). Standard physiological monitoring (pulse, 
blood pressure, oxygen saturation, and electrocardiogram) 
was carried out during the procedure. Antibiotic prophylaxis 
administrated parentally was 2 g cefazolin. Both the right and left 
femoral veins were cannulated with 80-cm long 10 French sheaths 
to facilitate the passage of large-diameter balloons and stents.
The tight stenosis of the SVC and left BCV was crossed with 
a 5-Fr vertebral curve catheter (Terumo, Tokyo, Japan) and a 
0.035-inch-angled hydrophilic guidewire (Terumo) via a femoral 
approach, and an SVC angiogram was carried out. Results showed 
a large filling defect of the SVC and left BCV stenosis with the 
presence of collateral veins (Figure 1A).
As it was not possible to cross the SVC and right BCV from the 
right femoral approach, the right basilic vein was punctured with 
a 20-G needle. A 45-cm long six-French introducer sheath was 
inserted and a phlebography was performed, revealing a subtotal 
stenosis of the right BCV in its central two-thirds with multiple 
collateral channels (Figure 1B). Mechanical recanalization of the 
right BCV and SVC occlusion was achieved with a 0.035-inch-
angled hydrophilic guidewire from access through the basilic 
vein (Terumo) supported by a vertebral curve 5-French catheter 
(Terumo). When the guidewire had traversed the occluded seg-
ment, it was grasped with a one-loop snare on the opposite side 
from the femoral approach and retrieved through the hemostatic 
valve sheath in a “teleferic” mode. This allowed future insertion 
of a balloon or a stent over the guidewire. Once both BCVs have 
been recanalized, the tip of the CVC was snared and withdrawn 
into the right subclavian vein using a trifoil EN-snare (Merit 
Medical, South Jordan, USA) through a right basilic vein access 
(Figure 2A). Conventional percutaneous balloon angioplasty of 
the left BCV and SVC with a 4-mm diameter balloon was per-
formed first (Passeo™ 35, Biotronik, Berlin, Germany). Bilateral 
kissing self-expandable Sinus-XL Flex stents (Optimed, Ettlingen, 
Germany) were deployed from the left BCV vein to the SVC 
(a 14-mm nominal diameter and 150 mm in length) and from the 
right BCV to the SVC (a 14-mm nominal diameter and 100 mm in 
length) (Figure 2B). The choice of stent diameters was guided by 
pretherapeutic data from CT with oversizing stents by up to 2-mm 
reference vessel diameter, in a non-involved BCV segment to help 
FIgURe 2 | (a) In an attempt to preserve the central venous catheter (CVC) for further chemotherapy, the CVC tip was removed before stenting from the superior 
vena cava into the right subclavian vein using a trifoil EN-snare from access through the basilic vein. (B) Bilateral kissing stents deployment (a 14-mm nominal 
diameter and 150- and 100-mm nominal lengths, Sinus-XL Flex, Optimed) and (C) balloon angioplasty (an 8-mm diameter balloon within the right stent, a 10-mm 
diameter balloon within the left stent) of superior vena cava (SVC) and the bilateral caudal portion of the brachiocephalic veins were performed. (D) Using a 
snare-loop technique, the CVC tip was removed in the SVC within the stent to facilitate subsequent chemotherapy.
FIgURe 3 | Left (a) and right (B) subclavian venograms obtained after stents placement showed restoration of superior vena cava and both brachiocephalic veins 
patency without collateral channels. No significant residual stenosis was observed within the stents.
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reduce delayed stent migration (8, 9). Kissing balloon angioplasty 
was then performed within the stents using a 10-mm diameter 
balloon (Armada™ 35, Abbott Vascular, Chicago, USA) into the 
left-sided stent and an 8-mm diameter balloon (Armada™ 35, 
Abbott Vascular) into the right-sided stent (Figure 2C).
Finally, the CVC was carefully replaced in the SVC within the 
stent (Figure 2D) using the same “snare-loop” technique.
A final cavogram showed improvement in the luminal 
diameter of the SVC and both BCVs with a free flow of contrast 
material into the right atrium and no collateral veins (Figure 3).
FIgURe 4 | A 3-month follow-up computed tomography (axial sections and coronal section in maximum intensity projection) demonstrated bilateral stents patency 
without collateral veins. The left-sided stent, which ensures head and neck venous drainage, had a larger expansion than the right-sided one.
4
Volpi et al. SVC Endovascular Reconstruction Preserving CVC
Frontiers in Surgery | www.frontiersin.org January 2018 | Volume 5 | Article 4
Intravenous 7,000-IU heparin (5,000-lU heparin bolus at the 
beginning of the procedure followed by an administration of 
2,000 IU after balloon angioplasty) was given via femoral venous 
sheath during the procedure. The procedure was successfully 
completed within 2 h.
Follow-up
The patient experienced quick relief of symptoms and was dis-
charged home 48 h later, with a prescription of 60 mg enoxaparin 
and 100 mg/day acetylsalicylic acid for 3 months. No procedure-
related complications occurred. The sixth round of chemotherapy 
(carboplatine and etoposide) was administrated a week after reca- 
nalization.
At a 3-month follow-up, the patient was asymptomatic with-
out recurrence of his previous symptoms, and no mechanical 
problem of the CVC was observed. CT venography showed stents 
expansion and patency with no collateral drainage (Figure 4).
The patient died 4 months following the stenting procedure. 
The leading cause of death was neurologic complications related 
to brain metastasis.
DIsCUssIoN
The treatment of SVC syndrome using percutaneous translu-
minal stenting is a well-accepted technique with usually rapid 
symptom relief in these patients (10–12). The complications of 
this procedure including rupture of the SVC or stent migration 
are rare (12–14).
In our institution as in many centers, self-expanding bare-
metal stents are the most common types of stents usually deployed 
in SVC obstructions (9, 12, 15, 16). Balloon-expandable stents are 
not recommended because of vein diameter differences between 
the distal- and proximal-landing zones and the short length of 
stents. Even if the use of covered stents versus bare-metal stents 
has suggested superior patency rates with covered stents after 
12  months in malignant SVC obstruction (17), covered stents 
should be used with caution due to concerns of stent migration 
and covering venous collaterals, particularly if placing a covered 
stent across the brachiocephalic confluence. Slow-balloon pre- 
dilatation is required if the occlusive lesion precludes the passage 
of the stent delivery system. We also routinely perform post-stent 
dilatation if there is a >30% residual stenosis. This appears to be 
required in most of the patients (7, 15).
Data on the performance of bilateral stenting are limited. Dyet 
et al. stated that they had discontinued bilateral stent placement 
in SVC syndrome, having seen that unilateral placement was 
also clinically effective (16). Two studies found equally good 
initial clinical success in both groups, but a higher proportion 
of obstructive complications were seen in the bilateral group 
(18, 19). The bilateral technique is technically more demanding, 
and it is also more expensive and time-consuming.
When both BCVs are invaded by the tumor, unilateral BCV 
revascularization is sufficient and provides higher flow through 
the stent than when both BCVs are revascularized (20). The 
choice of recanalization side is based on the preferential head and 
neck venous drainage side or the inability to access both sides 
(1, 20, 21). CT phlebography is usually the modality of choice to 
determine the location of SVC obstruction and the involvement 
of BCV, and to provide an evaluation of head and neck venous 
drainage via internal jugular vein size (21). In our case, the left 
IJV vein was the major venous return from the head and neck, 
whereas the right IJV was thin. Therefore, the SVC downstream 
and the left BCV had to be recanalized to relieve symptoms.
Three options were considered. The first one was an SVC stent-
ing with repositioning of the CVC just before and after stenting 
(1, 22, 23). CVCs are usually removed before stenting to prevent 
catheter fixation between the stent and the vessel wall with the 
associated risk of catheter dysfunction or catheter loss (24). To 
avoid catheter removal and the associated strain and risks of a 
new CVC insertion for the patient, a technique of repositioning 
before and after stenting was proposed, as previously described by 
Qanadli et al. (25). This option may have been considered in case 
of focal SVC stenosis without BCV veins involvement.
The second option would have been the SVC and left BCV 
stenting to assure head and neck venous drainage without preserv-
ing the CVC. This option may have led to catheter dysfunction or 
catheter loss. However, chemotherapy is also the standard form 
of treatment of malignant SVC syndrome. After rapid relief of 



























F/61 (22) Hickmann R SCV/NS 0/0 1/0 Ipsilateral IVJ 0 1/0 0
M/61 (22) Hickmann R SCV/NS 1/0 1/0 Ipsilateral IVJ 0 1/0 0
F/76 (22) Hickmann L IJV/NS 0/0 1/0 Ipsilateral CV 0 0/1 0
M/61 (22) Hickmann L IJV/NS 1/0 1/0 Ipsilateral CV 0 0/1 0
M/63 (22) Hickmann L IJV/NS 0/0 1/0 Ipsilateral CV 0 1/0 0
F/77 (22) Hickmann R IJV/NS 0/0 1/0 Ipsilateral CV 0 1/0 0
F/24 (22) ICVC L BCV/NS 1/0 0/1 Contralateral CV 1 0/0 0
M/51 (22) ICVC L BCV/NS 1/0 0/1 Contralateral CV 1 0/0 0
M/48 (24) ICVC L SCV/SVC 0/1 0/0 Ipsilateral BV 1 0/0 0
F/49 (25) ICVC R SCV/SVC 0/1 0/0 Ipsilateral BV 1 0/0 0
F/44 (28) ICVC L SCV/SVC 1/0 0/0 R femoral vein 1 0/0 0
M/54 (29) ICVC L SCV/SVC 1/0 0/1 R IJV + L IJV 1 0/1 0
M/60a ICVC R SCV/SVC 0/1 1/1 Ipsilateral BV + R femoral vein 2 1/1 1
BCV, brachiocephalic vein; BV, basilica vein; CVC, central venous catheters; CV, cubital vein; ICVC, implanted central venous catheter; IJV, internal jugular vein; L, left; NS, not 
specified; R, right; SVC, superior vena cava.
aRefers to our article.
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symptoms after stenting, there is a need to continue the scheduled 
coadjuvant treatments (chemotherapy, radiotherapy, or both) 
(26). In this situation, unilateral stenting while preserving CVC 
access by leaving a peripherally inserted central catheter or an 
arm port CVC over the basilica vein access guidewire would have 
been another possibility.
A bilateral kissing stent deployment in order to cover the 
SVC downstream and both BCVs with CVC repositioning was 
the third and preferred option. This SVC reconstruction had two 
different objectives for each side. Left recanalization assured head 
and neck venous drainage, whereas right recanalization permit-
ted CVC repositioning and subsequent in-stent replacement.
A last possibility is to deploy two different self-expandable 
stents, with a larger one in the SVC and left BCV. A larger stent 
would provide higher flow through it, reducing the risk of 
obstructive complications (27). In our case, the priority was to 
keep the left-sided flow patency to ensure head and neck drain-
age. We have oversized balloon angioplasty within the left-sided 
stent (a 10-mm diameter) comparatively to balloon angioplasty 
within the right-sided stent (an 8-mm diameter). Follow-up CT 
confirmed a larger expansion of the left-sided stent.
We reviewed published case reports of SVC stenting with 
catheter repositioning (Table 1). All previous cases reported CVC 
repositioning through the stent used in the treatment of SVC syn-
drome (22, 24, 25, 28, 29). Only two patients had SVC occlusion.
Our case reports for the first time SVC and BCV reconstruction, 
for the purpose of not only treating venous obstruction but also 
preserving CVC function. Because of the bilateral involvement 
of BCV, one axis (one stent) was used to treat venous obstruction 
and the second one (one stent) was implanted to create a venous 
access and save CVC function.
CoNClUDINg ReMaRKs
In conclusion, even if unilateral stent placement is preferable 
in most patients with SVC syndrome because it is as clinically 
efficient as bilateral placement while offering lower cost, easier 
procedure, and lower rates of complications, bilateral stenting has 
to be considered in selected patients to avoid catheter loss or to 
facilitate subsequent catheter insertion. The procedure is safe and 
improves patients’ quality of life without the need of a second 
intervention for CVC placement.
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